2025 Q4 -tulosraportti
Vain PDF
23 päivää sitten
0,0823 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 215 | - | - | ||
| 598 | - | - | ||
| 83 | - | - | ||
| 85 | - | - | ||
| 83 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 t sitten · MuokattuFrom DI: Daytrader tricked trading robot – convicted A Swedish daytrader tricked a stock market robot into moving its prices, so he could trade at better levels. Now the man has been convicted of market manipulation. They should be allowed to cheat everyone else, with the help of the courts.
·13 t sitten · MuokattuAnd then just 20 øre down at close, oops no almost 40 øre 🤮🤮🤮🤮- ·22 t sittenImpressive that it is legal to be criminal when one is just short sellers, FI, banks and others in the financial world.
·21 t sittenDon't worry, they'll regret it! Look at pipline, strong managenet, board, and in the combined insider holdings, it wouldn't surprise me if we soon see some ok serious buys😉 
·1 päivä sitten · MuokattuIf one wants to do some research oneself, here is an interesting document. Together with ChatGPT, I have uploaded Redeye's overview in an Excel sheet and this document, and asked what ChatGPT thinks about it. One can easily buy into 4-5 Phase I projects already now if one wants and put in an F1->F2 LoA now and say it's a fair price - personally I just won't pay for Phase 1 until we are there!l A bit of the ChatGPT dialogue comes here, if one finds it fun - it's a bit of an attempt to take emotions out, so one can always add a bit related to it afterwards: When the individual projects then enter clinical phase - and further to the next phase, one can adjust LoA - the same can be done if new projects, new agreements, new money come in, or if a project is closed. Unfortunately, I cannot upload an Excel sheet, but I think one can quickly make it oneself from Redeye's analysis - that's what I have done myself. ----------------------------------------- Question to ChatGPT: If you were to put some LoA into the attached Excel sheet, what would you put in column M - and would you add something to the calculation. What do you think about the calculation in column O Thought for 6m 19s Yes. I would set column M like this in a 1-factor model: SAN711 Epilepsy: 10% SAN711 Essential Tremor: 18% Tesomet HO/PwS: 25% Tesofensine Obesity: 85% AstronauTx Alzheimer: 2% SAN2355 Epilepsy: 4% SAN2465 Major Depression: 2% Boehringer Schizophrenia: 2% SAN2668 ESES/DEEs: 5% SAN2219 Epilepsy: 3% SAN903: 5% CAD1883: 10% (only if you want to keep the row active) The background is especially that SAN2219 and SAN2465 are still preclinical, SAN2668 first moves towards Phase I in 2026, Tesomet is paused due to funding, Tesofensine is regulatory/NDA-submitted in Mexico, and SAN903 is “ready for clinical studies”. ACP-711/SAN711 has completed Phase I and aims for Phase II in essential tremor. BIO 2011–2020 also supports lower probabilities for CNS than for the average, while rare disease is higher. The most important thing, however, is: I would add an extra factor to the calculation — not mix everything into LoA alone. Add, for example, an auxiliary column with: Execution / funding / partner factor This is especially relevant for: Tesomet (paused) SAN711 epilepsy (more optionality than lead program) discovery/collab-assets like AstronauTx/BI Then the model becomes: Risked value = Unrisked NPV × Technical LoA × Execution factor https://go.bio.org/rs/490-EHZ-999/images/ClinicalDevelopmentSuccessRates2011_2020.pdf?utm_source=chatgpt.com- ·2 päivää sittenShorts are wrong! This is a top-tier company -now on sale.
·1 päivä sittenMy case says they should be at 20-24 now. Therefore, I buy below 15 and sell above 25. Roughly.·1 päivä sitten · MuokattuHow wonderful it is to see someone who is closer to my view than all the fanatics. There aren't many who dare to say it out loud. Agreed, except for your fair value - my calculation says 12 on their pipeline and collaborations and statistical LoA and my buying window is 12-15. I added at 14.66 today. When we have an approval in Mexico and a new agreement I am ready to buy up to around 20. Ref my other post regarding Redeye and LoA I bear 6 - base 12 - bull 26 under different assumptions. In my opinion, it is completely hopeless to buy at 17-20 now
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
23 päivää sitten
0,0823 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sitten · MuokattuFrom DI: Daytrader tricked trading robot – convicted A Swedish daytrader tricked a stock market robot into moving its prices, so he could trade at better levels. Now the man has been convicted of market manipulation. They should be allowed to cheat everyone else, with the help of the courts.
- ·13 t sitten · MuokattuAnd then just 20 øre down at close, oops no almost 40 øre 🤮🤮🤮🤮
- ·22 t sittenImpressive that it is legal to be criminal when one is just short sellers, FI, banks and others in the financial world.·21 t sittenDon't worry, they'll regret it! Look at pipline, strong managenet, board, and in the combined insider holdings, it wouldn't surprise me if we soon see some ok serious buys😉
- ·1 päivä sitten · MuokattuIf one wants to do some research oneself, here is an interesting document. Together with ChatGPT, I have uploaded Redeye's overview in an Excel sheet and this document, and asked what ChatGPT thinks about it. One can easily buy into 4-5 Phase I projects already now if one wants and put in an F1->F2 LoA now and say it's a fair price - personally I just won't pay for Phase 1 until we are there!l A bit of the ChatGPT dialogue comes here, if one finds it fun - it's a bit of an attempt to take emotions out, so one can always add a bit related to it afterwards: When the individual projects then enter clinical phase - and further to the next phase, one can adjust LoA - the same can be done if new projects, new agreements, new money come in, or if a project is closed. Unfortunately, I cannot upload an Excel sheet, but I think one can quickly make it oneself from Redeye's analysis - that's what I have done myself. ----------------------------------------- Question to ChatGPT: If you were to put some LoA into the attached Excel sheet, what would you put in column M - and would you add something to the calculation. What do you think about the calculation in column O Thought for 6m 19s Yes. I would set column M like this in a 1-factor model: SAN711 Epilepsy: 10% SAN711 Essential Tremor: 18% Tesomet HO/PwS: 25% Tesofensine Obesity: 85% AstronauTx Alzheimer: 2% SAN2355 Epilepsy: 4% SAN2465 Major Depression: 2% Boehringer Schizophrenia: 2% SAN2668 ESES/DEEs: 5% SAN2219 Epilepsy: 3% SAN903: 5% CAD1883: 10% (only if you want to keep the row active) The background is especially that SAN2219 and SAN2465 are still preclinical, SAN2668 first moves towards Phase I in 2026, Tesomet is paused due to funding, Tesofensine is regulatory/NDA-submitted in Mexico, and SAN903 is “ready for clinical studies”. ACP-711/SAN711 has completed Phase I and aims for Phase II in essential tremor. BIO 2011–2020 also supports lower probabilities for CNS than for the average, while rare disease is higher. The most important thing, however, is: I would add an extra factor to the calculation — not mix everything into LoA alone. Add, for example, an auxiliary column with: Execution / funding / partner factor This is especially relevant for: Tesomet (paused) SAN711 epilepsy (more optionality than lead program) discovery/collab-assets like AstronauTx/BI Then the model becomes: Risked value = Unrisked NPV × Technical LoA × Execution factor https://go.bio.org/rs/490-EHZ-999/images/ClinicalDevelopmentSuccessRates2011_2020.pdf?utm_source=chatgpt.com
- ·2 päivää sittenShorts are wrong! This is a top-tier company -now on sale.·1 päivä sittenMy case says they should be at 20-24 now. Therefore, I buy below 15 and sell above 25. Roughly.·1 päivä sitten · MuokattuHow wonderful it is to see someone who is closer to my view than all the fanatics. There aren't many who dare to say it out loud. Agreed, except for your fair value - my calculation says 12 on their pipeline and collaborations and statistical LoA and my buying window is 12-15. I added at 14.66 today. When we have an approval in Mexico and a new agreement I am ready to buy up to around 20. Ref my other post regarding Redeye and LoA I bear 6 - base 12 - bull 26 under different assumptions. In my opinion, it is completely hopeless to buy at 17-20 now
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 215 | - | - | ||
| 598 | - | - | ||
| 83 | - | - | ||
| 85 | - | - | ||
| 83 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
2025 Q4 -tulosraportti
Vain PDF
23 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
0,0823 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sitten · MuokattuFrom DI: Daytrader tricked trading robot – convicted A Swedish daytrader tricked a stock market robot into moving its prices, so he could trade at better levels. Now the man has been convicted of market manipulation. They should be allowed to cheat everyone else, with the help of the courts.
- ·13 t sitten · MuokattuAnd then just 20 øre down at close, oops no almost 40 øre 🤮🤮🤮🤮
- ·22 t sittenImpressive that it is legal to be criminal when one is just short sellers, FI, banks and others in the financial world.·21 t sittenDon't worry, they'll regret it! Look at pipline, strong managenet, board, and in the combined insider holdings, it wouldn't surprise me if we soon see some ok serious buys😉
- ·1 päivä sitten · MuokattuIf one wants to do some research oneself, here is an interesting document. Together with ChatGPT, I have uploaded Redeye's overview in an Excel sheet and this document, and asked what ChatGPT thinks about it. One can easily buy into 4-5 Phase I projects already now if one wants and put in an F1->F2 LoA now and say it's a fair price - personally I just won't pay for Phase 1 until we are there!l A bit of the ChatGPT dialogue comes here, if one finds it fun - it's a bit of an attempt to take emotions out, so one can always add a bit related to it afterwards: When the individual projects then enter clinical phase - and further to the next phase, one can adjust LoA - the same can be done if new projects, new agreements, new money come in, or if a project is closed. Unfortunately, I cannot upload an Excel sheet, but I think one can quickly make it oneself from Redeye's analysis - that's what I have done myself. ----------------------------------------- Question to ChatGPT: If you were to put some LoA into the attached Excel sheet, what would you put in column M - and would you add something to the calculation. What do you think about the calculation in column O Thought for 6m 19s Yes. I would set column M like this in a 1-factor model: SAN711 Epilepsy: 10% SAN711 Essential Tremor: 18% Tesomet HO/PwS: 25% Tesofensine Obesity: 85% AstronauTx Alzheimer: 2% SAN2355 Epilepsy: 4% SAN2465 Major Depression: 2% Boehringer Schizophrenia: 2% SAN2668 ESES/DEEs: 5% SAN2219 Epilepsy: 3% SAN903: 5% CAD1883: 10% (only if you want to keep the row active) The background is especially that SAN2219 and SAN2465 are still preclinical, SAN2668 first moves towards Phase I in 2026, Tesomet is paused due to funding, Tesofensine is regulatory/NDA-submitted in Mexico, and SAN903 is “ready for clinical studies”. ACP-711/SAN711 has completed Phase I and aims for Phase II in essential tremor. BIO 2011–2020 also supports lower probabilities for CNS than for the average, while rare disease is higher. The most important thing, however, is: I would add an extra factor to the calculation — not mix everything into LoA alone. Add, for example, an auxiliary column with: Execution / funding / partner factor This is especially relevant for: Tesomet (paused) SAN711 epilepsy (more optionality than lead program) discovery/collab-assets like AstronauTx/BI Then the model becomes: Risked value = Unrisked NPV × Technical LoA × Execution factor https://go.bio.org/rs/490-EHZ-999/images/ClinicalDevelopmentSuccessRates2011_2020.pdf?utm_source=chatgpt.com
- ·2 päivää sittenShorts are wrong! This is a top-tier company -now on sale.·1 päivä sittenMy case says they should be at 20-24 now. Therefore, I buy below 15 and sell above 25. Roughly.·1 päivä sitten · MuokattuHow wonderful it is to see someone who is closer to my view than all the fanatics. There aren't many who dare to say it out loud. Agreed, except for your fair value - my calculation says 12 on their pipeline and collaborations and statistical LoA and my buying window is 12-15. I added at 14.66 today. When we have an approval in Mexico and a new agreement I am ready to buy up to around 20. Ref my other post regarding Redeye and LoA I bear 6 - base 12 - bull 26 under different assumptions. In my opinion, it is completely hopeless to buy at 17-20 now
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 215 | - | - | ||
| 598 | - | - | ||
| 83 | - | - | ||
| 85 | - | - | ||
| 83 | - | - |
Välittäjätilasto
Dataa ei löytynyt